President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella,

During market turbulence, investors turn to dividend-yielding stocks. Benzinga provides analyst rati

President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11

https://youtu.be/H_RititNE8U

The Trump administration is reportedly considering an executive order on vaccines and autism as earl

Vaccine maker GlaxoSmithKline Pharmaceuticals reported a 15.7% rise in first-quarter profit on Monda

British biotech firm Relation Therapeutics said on Wednesday it ​had entered into a research ‌collab

GSK beats Q2 earnings and revenue estimates, reaffirms 2026 guidance and unveils a new cost-saving p

https://www.gsk.com/en-gb/media/press-releases/cabenuva-demonstrates-superiority-to-daily-oral-thera

GSK plc (GSK) Q2 2026 Earnings Call Transcript

GSK NYSE: GSK reported second-quarter sales growth of 5% at constant exchange rates to more than £8.

GSK beats Q2 revenue and earnings estimates, launches a $2.52B cost-savings program, and updates its

GSK delivered healthy Q2 and H1 2026 results, with the highlight being core turnover and EPS growth

GSK PLC (LSE:GSK, NYSE:GSK) shares jumped to a three-month high after the drugmaker beat second-quar

GSK PLC (LSE:GSK, NYSE:GSK) shares jumped to a three-month high after the drugmaker beat second-quar

U.S. stocks mixed, Dow Jones up 300 points. Shares of Sherwin-Williams rose 7.8% after reporting bet

GSK (GSK) came out with quarterly earnings of $1.36 per share, beating the Zacks Consensus Estimate

The U.K. drugmaker is targeting annual savings of $2.52 billion by 2029, as Chief Executive Luke Mie

In times of market turbulence, dividend-yielding stocks are popular for investors. Check out analyst

GSK (NYSE:GSK) affirms FY2026 Adj EPS guidance from $4.90-$5.00 to $4.90-$5.00 vs $4.79 analyst esti

GSK (NYSE:GSK) reported quarterly earnings of $1.35 per share which beat the analyst consensus estim

Results add to a growing body of positive late-stage evidence for Ris-Rez, including recent pivotal

GSK on Tuesday ​beat second-quarter profit ‌expectations and launched a £1.9 ​billion ($2.52 billion

British drugmaker GSK said on Tuesday that it will invest £400 million ($531.12 million) over 3 year

GSK on ​Tuesday said ‌partner Hansoh Pharmaceutical's ​experimental ​drug Ris-Rez met ⁠its main ​goa

Bank of New York Mellon Corp lowered its position in GSK PLC Sponsored ADR (NYSE: GSK) by 13.8% duri

GSK Canada today announced the approval of Shingrix (GSK's Recombinant Zoster Vaccine or RZV) in

The FTSE 100 Index was little changed this week as investors assessed the escalating UK-Iran crisis,

Summit announces updated HARMONi overall survival data and partners with Arcus to test ivonescimab i

GSK secures early FDA approval for Jideytro, its first lung cancer therapy, backed by strong ARROS-1

GSK's Specialty Medicines unit is expected to post double-digit CER growth in Q2, driven by newer HI

Approval based on ARROS-1 phase I/II trial demonstrating meaningful and durable responses in patient

GSK wins early FDA approval for Jideytro, a targeted treatment for adults with advanced ROS1-positiv

GSK plc (LSE/NYSE:GSK) today announced the US Food and Drug Administration (FDA) has approved Jideyt

GSK said ​on ‌Wednesday the ​U.S. ​FDA has approved ⁠its ​drug ​for adults with ​a ​form of lung ‌ca

Trump says imported generic drugs face 0% tariffs for 2 years, before 100% and then 200% duties.

GSK stops development of chronic cough drug camlipixant after mixed Phase 3 results; continue testin

Investors turn to dividend-yielding stocks during market turbulence. Benzinga's Analyst Stock Ra

GSK Jemperli shows sustained complete responses in dMMR/MSI-H rectal cancer, potentially eliminating

GSK-backed Ris-Rez posts positive Phase 3 survival data in small-cell lung cancer as the company mov

Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) today announces that risvutatug reze

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Sino Biopharma expanded its GSK partnership in China and signed an AstraZeneca licensing deal worth

Elizabeth Warren warns Trump's law pushed children off Medicaid and CHIP in many states, while a

Investors turn to dividend-yielding stocks in turbulent markets. Benzinga offers latest analyst rati

FDA approves GSK and SPRO's Utebzi, the first oral carbapenem for cUTIs. Launch planned for late

https://www.gsk.com/en-gb/media/press-releases/utebzi-tebipenem-pivoxil-approved-in-the-us-for-adult

GSK announced today that Health Canada has approved Exdensur (depemokimab) for two indications:As an

During market turbulence, investors turn to dividend-yielding stocks. Benzinga offers latest analyst

GSK plc (LSE/NYSE:GSK) today announced that momelotinib, a JAK inhibitor with a differentiated mecha